Precision medicine has the potential to transform lives, one person at a time. Recognising the variability in genes, environment, and lifestyle allows for earlier detection of disease and identification of at-risk populations. This enables patients, physicians, payers, and providers to take proactive measures. Precision medicine supports more targeted and effective treatment decisions with detailed insights into the factors driving a person’s cancer, such as specific biomarkers or mutations. Additionally, it can reduce healthcare costs by shortening hospital stays, improving resource efficiency, and supporting longer, healthier working lives.^1,2

At J&J, our focus extends beyond researching, developing, and delivering precision therapies. We are committed to removing barriers that limit access to these treatments and working alongside key partners to enhance diagnostics.

Innovation is at the heart of our approach, driving a pipeline focused on developing precision treatments for challenging tumour types, with a particular emphasis on bladder and lung cancer. Our involvement in the UK Biobank Whole Genome Sequencing (WGS) Project has been a key milestone, contributing to the analysis of data from 500,000 volunteers. This vast dataset is pivotal in accelerating personalised discoveries that can shape the future of cancer treatment.

We believe that meaningful change is driven by collaboration. That’s why we are working with leading organisations to co-develop diagnostic tools focused on identifying biomarkers in cancer. Together, we are unlocking new potential for patients and the healthcare system.